Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study - PubMed (original) (raw)
Clinical Trial
. 2005 May;90(5):2816-22.
doi: 10.1210/jc.2004-1774. Epub 2005 Feb 22.
E Seeman, M C De Vernejoul, S Adami, J Compston, C Phenekos, J P Devogelaer, M Diaz Curiel, A Sawicki, S Goemaere, O H Sorensen, D Felsenberg, P J Meunier
Affiliations
- PMID: 15728210
- DOI: 10.1210/jc.2004-1774
Free article
Clinical Trial
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
J Y Reginster et al. J Clin Endocrinol Metab. 2005 May.
Free article
Abstract
Background: Strontium ranelate, a new oral drug shown to reduce vertebral fracture risk in postmenopausal women with osteoporosis, was studied in the Treatment of Peripheral Osteoporosis (TROPOS) study to assess its efficacy and safety in preventing nonvertebral fractures also.
Methods: Strontium ranelate (2 g/d) or placebo were randomly allocated to 5091 postmenopausal women with osteoporosis in a double-blind placebo-controlled 5-yr study with a main statistical analysis over 3 yr of treatment.
Findings: In the entire sample, relative risk (RR) was reduced by 16% for all nonvertebral fractures (P = 0.04), and by 19% for major fragility fractures (hip, wrist, pelvis and sacrum, ribs and sternum, clavicle, humerus) (P = 0.031) in strontium ranelate-treated patients in comparison with the placebo group. Among women at high risk of hip fracture (age > or = 74 yr and femoral neck bone mineral density T score < or = -3, corresponding to -2.4 according to NHANES reference) (n = 1977), the RR reduction for hip fracture was 36% (P = 0.046). RR of vertebral fractures was reduced by 39% (P < 0.001) in the 3640 patients with spinal x-rays and by 45% in the subgroup without prevalent vertebral fracture. Strontium ranelate increased bone mineral density throughout the study, reaching at 3 yr (P < 0.001): +8.2% (femoral neck) and +9.8% (total hip). Incidence of adverse events (AEs) was similar in both groups.
Conclusion: This study shows that strontium ranelate significantly reduces the risk of all nonvertebral and in a high-risk subgroup, hip fractures over a 3-yr period, and is well tolerated. It confirms that strontium ranelate reduces vertebral fractures. Strontium ranelate offers a safe and effective means of reducing the risk of fracture associated with osteoporosis.
Similar articles
- Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
Adami S. Adami S. Bone. 2006 Feb;38(2 Suppl 1):23-7. doi: 10.1016/j.bone.2005.08.028. Epub 2006 Jan 24. Bone. 2006. PMID: 16434247 Clinical Trial. - Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ. Reginster JY, et al. Arthritis Rheum. 2008 Jun;58(6):1687-95. doi: 10.1002/art.23461. Arthritis Rheum. 2008. PMID: 18512789 Clinical Trial. - Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
Seeman E, Boonen S, Borgström F, Vellas B, Aquino JP, Semler J, Benhamou CL, Kaufman JM, Reginster JY. Seeman E, et al. Bone. 2010 Apr;46(4):1038-42. doi: 10.1016/j.bone.2009.12.006. Epub 2009 Dec 21. Bone. 2010. PMID: 20026265 Clinical Trial. - Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. O'Donnell S, et al. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326. doi: 10.1002/14651858.CD005326.pub2. Cochrane Database Syst Rev. 2006. PMID: 16856092 Updated. Review. - Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy.
Blake GM, Fogelman I. Blake GM, et al. Clin Interv Aging. 2006;1(4):367-75. doi: 10.2147/ciia.2006.1.4.367. Clin Interv Aging. 2006. PMID: 18046914 Free PMC article. Review.
Cited by
- The influence of SrO and CaO in silicate and phosphate bioactive glasses on human gingival fibroblasts.
Massera J, Kokkari A, Närhi T, Hupa L. Massera J, et al. J Mater Sci Mater Med. 2015 Jun;26(6):196. doi: 10.1007/s10856-015-5528-x. Epub 2015 Jun 23. J Mater Sci Mater Med. 2015. PMID: 26099346 - Strontium enhances osseointegration of calcium phosphate cement: a histomorphometric pilot study in ovariectomized rats.
Baier M, Staudt P, Klein R, Sommer U, Wenz R, Grafe I, Meeder PJ, Nawroth PP, Kasperk C. Baier M, et al. J Orthop Surg Res. 2013 Jun 7;8:16. doi: 10.1186/1749-799X-8-16. J Orthop Surg Res. 2013. PMID: 23758869 Free PMC article. - Role of Calcitonin and Strontium Ranelate in Osteoporosis.
Ghani A, Arfee S. Ghani A, et al. Indian J Orthop. 2023 Dec 4;57(Suppl 1):115-119. doi: 10.1007/s43465-023-01034-x. eCollection 2023 Dec. Indian J Orthop. 2023. PMID: 38107820 Free PMC article. - Mechanism of action of strontium ranelate: what are the facts?
Fonseca JE, Brandi ML. Fonseca JE, et al. Clin Cases Miner Bone Metab. 2010 Jan;7(1):17-8. Clin Cases Miner Bone Metab. 2010. PMID: 22461285 Free PMC article. No abstract available. - An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.
Borgström F, Jönsson B, Ström O, Kanis JA. Borgström F, et al. Osteoporos Int. 2006 Dec;17(12):1781-93. doi: 10.1007/s00198-006-0193-z. Epub 2006 Sep 29. Osteoporos Int. 2006. PMID: 17009083
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical